Check-Cap CHEK - Daily June 2021CHEK will be looking for FDA approval by early 2023. US Pivotal Study will take place in 2022.
−19.108MUSD
5.217M
About Check-Cap Ltd.
Sector
Industry
CEO
Alex Ovadia
Website
Headquarters
Isfiya
Employees (FY)
85
Founded
2005
ISIN
IL0011336851
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
Chek Harmonics: Fishing for Round ThreeHere, we have what appears to be a clear 3-drive pattern. I noticed that each spike is on a Monday, within one plus or minus approximately 1 week of a quadruple witching day. Furthermore, time ratios indicated the pop COULD happen anytime between the purple vertical lines; however, the pattern is
$CHEK PT 5 and way higherCheck-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X
Third Technical Analysis - CHEK Based on the historical data that the chart presents, the bottom of the trend is estimated to be at $1.92; however, there is both technical and psychological support at $ 2. This indicates there could be a slight dip under $2 temporarily in the upcoming days ( however, this seems unlikely ). Followi
Chek Harmonics: 1-2-3 Go!It's a long wait here, from this perspective, but the entry and quick exit would be a phenomenal trade. Check it out and load up when price satisfies the buy zone criteria and when the timing is right!
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan®
today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S.
The pivotal study wil
premarket mover, possible targets $9, $12Please note:
- I'm just sharing my view. its not a recommendation for buying or selling.
- penny stocks moves most of the times are " pump n dump". don't chase them, and you must have an exit plan.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
